Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer.
Immunotherapy
Lung cancer
Siglec-15
Tumor biomarkers
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
01
08
2023
accepted:
18
09
2023
medline:
27
11
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
ppublish
Résumé
Lung cancer has been the main cause of cancer mortality worldwide. Furthermore, lung cancer rates of new cases per year evidenced a large incidence of this neoplasm in both men and women. Because there is no biomarker for early detection, it is frequently detected late, at an advanced state. The introduction of multiple lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations has modified the therapy of lung cancer. Immunotherapy advances have resulted in substantial improvements in overall survival and disease-free survival, making immune checkpoint inhibitors (ICIs) a potential option for lung cancer treatment. Current PD-1/PD-L1/CTLA-4 immunotherapies have resulted in important response and survival rates. However, existing medicines only function in around 20% of unselected, advanced NSCLC patients, and primary and acquired resistance remain unsolved obstacles. Therefore, precise predictive indicators must be identified to choose the best patients for ICI treatment. Thus, Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) stands out as a potential tumor biomarker, with distinctive expression in normal tissues, in tumor immune involvement, and a high structural similarity to PD-L1. Understanding the tumor immune response and the search for new therapeutic targets leads to the improvement of therapeutic pathways directed at the tumor microenvironment. The present review aims to analyze Siglec-15 potential as a diagnostic, prognostic, and response biomarker in lung cancer, considering its results evidenced in the current literature.
Identifiants
pubmed: 37843557
doi: 10.1007/s00432-023-05437-z
pii: 10.1007/s00432-023-05437-z
doi:
Substances chimiques
B7-H1 Antigen
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Proto-Oncogene Proteins
0
Biomarkers, Tumor
0
Sialic Acid Binding Immunoglobulin-like Lectins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
17651-17661Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Aguirre-Ducler A et al (2022) Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling. J Immunother Cancer 10(7):e005113
pubmed: 35868661
pmcid: 9315908
Alfranca YL, Garcia MEO, Rueda AG, Ballesteros PÁ, Rodríguez DR, Velasco MT (2022) Blood biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer. J Clin Med 11(11):3245
pubmed: 35683629
pmcid: 9181575
Altorki NK et al (2019) The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer 19(1):9–31
pubmed: 30532012
pmcid: 6749995
American Cancer Society (2023) Facts and figures 2023. American Cancer Society, Atlanta
Angata T (2020) Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases. J Biomed Sci 27(1):1–7
Angata T, Varki NM, Varki A (2001) A second uniquely human mutation affecting sialic acid biology* 210. J Biol Chem 276(43):40282–40287
pubmed: 11546777
Angata T et al (2007) Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology 17(8):838–846
pubmed: 17483134
Antonia SJ et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929
pubmed: 28885881
Arasanz H et al (2022) Circulating low density neutrophils are associated with resistance to first line anti-PD1/PDL1 immunotherapy in non-small cell lung cancer. Cancers (basel) 14(16):3846. https://doi.org/10.3390/cancers14163846
doi: 10.3390/cancers14163846
pubmed: 36010840
Araujo LH et al (2018) Câncer de pulmão no Brasil. J Bras Pneumol 44:55–64
pubmed: 29538545
pmcid: 6104542
Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11(10):889–896
pubmed: 20856220
Bochner BS et al (2005) Glycan array screening reveals a candidate ligand for Siglec-8. J Biol Chem 280(6):4307–4312
pubmed: 15563466
Bornhöfft KF et al (2018) Siglecs: a journey through the evolution of sialic acid-binding immunoglobulin-type lectins. Dev Comp Immunol 86:219–231
pubmed: 29751010
Cognasse F et al (2015) The inflammatory role of platelets via their TLRs and Siglec receptors. Front Immunol 6:83
pubmed: 25784910
pmcid: 4345914
Dakubo GD et al (2007) Clinical implications and utility of field cancerization. Cancer Cell Int 7(1):1–12
Daly J, Carlsten M, O’dwyer M (2019) Sugar free: novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer. Front Immunol 10:1047
pubmed: 31143186
pmcid: 6521797
Ding P et al (2022) Glucosamine-phosphate N-acetyltransferase 1 and its DNA methylation can be biomarkers for the diagnosis and prognosis of lung cancer. J Clin Lab Anal 36(9):e24628
pubmed: 35929347
pmcid: 9459321
Domagala-Kulawik J (2015) The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res 4(2):177–190
pubmed: 25870800
pmcid: 4384216
El-Fattah A, Eslam E (2022) IDO/kynurenine pathway in cancer: possible therapeutic approaches. J Transl Med 20(1):1–13
Feng Y, Li N, Ren Y (2022) GNPNAT1 predicts poor prognosis and cancer development in non-small cell lung cancer. Cancer Manag Res 14:2419–2428
pubmed: 35975106
pmcid: 9375989
Gonzalez-Gil A et al (2018) Sialylated keratan sulfate proteoglycans are Siglec-8 ligands in human airways. Glycobiology 28(10):786–801
pubmed: 29924315
Han Y et al (2020) PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727–742
pubmed: 32266087
pmcid: 7136921
Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31–46
pubmed: 35022204
Hao JQ et al (2020) The significance of Siglec-15 expression in resectable non-small cell lung cancer. Neoplasma 67(6):1214–1222
pubmed: 32749846
Hendriks LE, on behalf of the ESMO Guidelines Committee et al (2023) Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(4):339–357
pubmed: 36872130
Hirsch F et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389(10066):299–311. https://doi.org/10.1016/S0140-6736(16)30958-8
doi: 10.1016/S0140-6736(16)30958-8
pubmed: 27574741
Hu X et al (2022) DDX24 promotes metastasis by regulating RPL5 in non-small cell lung cancer. Cancer Med 11:4513–4525
pubmed: 35864588
pmcid: 9741967
Huang M-Y et al (2021) Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther 219:107694
pubmed: 32980443
Huang J et al (2022a) LncRNA NBR2 regulates cancer cell stemness and predicts survival in non-small cell cancer patients by downregulating TGF-β1. Curr Pharm Biotechnol 24:1059–1069
Huang R et al (2022b) GRSF1 predicts an unfavorable prognosis and promotes tumorigenesis in lung adenocarcinoma based on bioinformatics analysis and in vitro validation. Ann Transl Med 10(13):747
pubmed: 35957724
pmcid: 9358520
Jiang C et al (2022) The potential mechanism of HDAC1-catalyzed histone crotonylation of caspase-1 in nonsmall cell lung cancer. Evidence Based Complementary Altern Med 2022:1–8
Kang F et al (2020) The diverse functions of Siglec-15 in bone remodeling and antitumor responses. Pharmacol Res 155:104728
pubmed: 32112821
Kang S et al (2022) Long noncoding RNA SNHG5 induces the NF-κB pathway by regulating miR-181c-5p/CBX4 axis to promote the progression of non-small cell lung cancer. Archivos de Bronconeumología 59:10–18
pubmed: 35963709
Kim JS et al (2022) Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance. J Cancer Res Clin Oncol 149:1–11
Lahiri A, Maji A, Potdar PD et al (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. https://doi.org/10.1186/s12943-023-01740-y
doi: 10.1186/s12943-023-01740-y
pubmed: 36810079
pmcid: 9942077
Larsen JE, Minna JD (2011) Molecular biology of lung cancer: clinical implications. Clin Chest Med 32(4):703–740
pubmed: 22054881
pmcid: 3367865
Li C et al (2022a) PAK4 expression is associated with the prognosis in non-small cell lung cancer. Medicine 101(33):e30050
pubmed: 35984204
pmcid: 9388013
Li D et al (2022b) Interfering with ITGB1-DT expression delays cancer progression and promotes cell sensitivity of NSCLC to cisplatin by inhibiting the MAPK/ERK pathway. Am J Cancer Res 12(7):2966–2988
pubmed: 35968342
pmcid: 9360236
Li M-J et al (2022c) Upregulation of CCNB2 and its perspective mechanisms in cerebral ischemic stroke and all subtypes of lung cancer: a comprehensive study. Front Integr Neurosci 16:854540
pubmed: 35928585
pmcid: 9344069
Li S et al (2022d) Elevated expression of the membrane-anchored serine protease TMPRSS11E in NSCLC progression. Carcinogenesis 43:1092–1102
pubmed: 35951670
Li Y, Liu X, Ma Z (2022e) EGFR, NF-κB and noncoding RNAs in precision medicine. Progr Mol Biol Transl Sci 190(1):189–218
Lin G et al (2022) C1QTNF6 regulated by miR-29a-3p promotes proliferation and migration in stage I lung adenocarcinoma. BMC Pulm Med 22(1):1–14
Mantovani A, Locati M (2013) Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 33(7):1478–1483
pubmed: 23766387
Nie J et al (2022) Circular RNA circFARSA promotes the tumorigenesis of non-small cell lung cancer by elevating B7H3 via sponging miR-15a-5p. Cell Cycle 21(24):2575–2589
pubmed: 35920698
pmcid: 9704387
Ning J et al (2022) Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma. Cell Death Discov 8(1):1–13
Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol 4(1):33–45
pubmed: 12511867
Punekar SR et al (2022) Immunotherapy in non-small cell lung cancer: past, present, and future directions. Front Oncol 12:877594
pubmed: 35992832
pmcid: 9382405
Rabinovich GA, Croci DO (2012) Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 36(3):322–335
pubmed: 22444630
Raju S, Joseph R, Sehgal S (2018) Review of checkpoint immunotherapy for the management of non-small cell lung cancer. ImmunoTargets Ther 7:63
pubmed: 30105218
pmcid: 6074780
Rashid S et al (2022) Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer. J Cell Physiol 237(3):1711–1719
pubmed: 34893976
Ren X (2019) Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. Cancer Biol Med 16(2):205
pubmed: 31516742
pmcid: 6713637
Schenck E et al (2021) 2020 innovation-based optimism for lung cancer outcomes. Oncologist 26(3):e454–e472. https://doi.org/10.1002/onco.13590
doi: 10.1002/onco.13590
Schmidt T et al (2012) Macrophage—tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. Cell Mol Life Sci 69(9):1391–1414
pubmed: 22076650
Shafi S et al (2022) Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Lab Investig 102:1–7
Shi Y et al (2022) Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. Thorac Cancer 13(2):219–227
pubmed: 34825500
Shields MD, Marin-Acevedo JA, Pellini B (2021) Immunotherapy for advanced non-small cell lung cancer: a decade of progress. Am Soc Clin Oncol Educ Book 41:e105–e127
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590
doi: 10.3322/caac.21590
pubmed: 31912902
Smart SK et al (2018) The emerging role of TYRO3 as a therapeutic target in cancer. Cancers 10(12):474
pubmed: 30501104
pmcid: 6316664
Spigel DR et al (2022) Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 40(12):1301
pubmed: 35108059
pmcid: 9015199
Takahata M et al (2007) Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis. Bone 41(1):77–86
pubmed: 17512814
Takamiya R et al (2013) The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12–Syk pathway. Glycobiology 23(2):178–187
pubmed: 23035012
Tiantian MA et al (2022) PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. Front Oncol 12:922899
Villalobos P, Wistuba II (2018) Lung cancer biomarkers. Hematol Oncol Clin N Am 31(1):13–29
Wang J et al (2019) Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med 25(4):656–666
pubmed: 30833750
pmcid: 7175920
Wimmel A et al (1999) Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. Cancer Interdiscip Int J Am Cancer Soc 86(1):43–49
Wu H-R et al (2019) Expedient assembly of Oligo-LacNAcs by a sugar nucleotide regeneration system: finding the role of tandem LacNAc and sialic acid position toward Siglec binding. Eur J Med Chem 180:627–636
pubmed: 31351394
Wyant T, Alteri R, Kalidas M (2022) About lung cancer what is lung cancer? American Cancer Society, Atlanta, pp 1–15
Zhang C et al (2019) Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway. J Cell Biochem 120(7):11642–11650
pubmed: 30767270
Zhou Y et al (2022) Effect of PFKFB4 on the prognosis and immune regulation of NSCLC and its mechanism. Int J Gen Med 15:6341–6353
pubmed: 35942289
pmcid: 9356739
Zöller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11(4):254–267
pubmed: 21390059